Skip to main content Skip to main navigation menu Skip to site footer

Association between Human Papilloma Virus (HPV) genotype and mutant protein 53 (p53) expression in cervical cancer

  • Samuel ,
  • Sharvianty Arifuddin ,
  • David Lotisna ,
  • M. Husni Cangara ,
  • Firdaus Hamid ,


Link of Video Abstract:


Background: Human Papilloma Virus (HPV) infection is the main cause of cervical cancer, a primary malignant tumor developing from squamous epithelial cells. HPV expresses oncoproteins E6 and E7, known to inactivate tumor suppressor proteins, one of which is protein 53 (p53). A promising biomarker for diagnosing and prognosis malignancies brought on by the HPV genotype is the identification of p53. This study investigates the association between p53 expression and HPV genotype in cervical cancer patients.

Method: This observational cross-sectional study involved patients diagnosed with cervical cancer on histopathological examination who met the requirements. The polymerase chain reaction (PCR) method was used to determine the HPV genotype, and an immunohistochemistry analysis was used to assess the level of p53 expression. A Chi-Square test is utilized to evaluate the association between the two variables.

Results: Of the 49 patients, there were 7 (14.3%) patients with HPV type 16, 13 (26.5%) with HPV type 18, 14 (26.5%) other types of HPV and 15 (30.6%) negatives for HPV. Examination of p53 expression showed that 17 (34.6%) samples had <10% expression, 17 (34.6%) had 10-50% expression, and 15 (30.8%) samples had >50% expression. There was no correlation between p53 expression and HPV genotype (p = 0.071). However, an association between p53 expression and cervical cancer's clinical stage was identified (p = 0.028).

Conclusion: Increased cervical cancer stage can be associated with increased p53 expression. Thus, p53 can be used as a predictor of cervical cancer stage. However, in cervical cancer, p53 expression cannot be associated with the HPV genotype.


  1. Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: A global health crisis. Cancer. 2017;123(13):2404-2412.
  2. Evriarti PR, Yasmon A. Patogenesis Human Papillomavirus (HPV) pada Kanker Serviks. JBMI. 2019;8(1):23-32.
  3. Buskwofie A, David-West G, Clare CA. A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc. 2020;112(2):229-232.
  4. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220-5227.
  5. Johnson CA, James D, Marzan A, Armaos M. Cervical Cancer: An Overview of Pathophysiology and Management. Semin Oncol Nurs. 2019;35(2):166-174.
  6. Manning AL, Dyson NJ. pRB, a tumor suppressor with a stabilizing presence. Trends in Cell Biology. 2011;21(8):433-44.
  7. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220-5227.
  8. Noraini MD, Siti-Aishah MA, Kwan SW. An immunohistochemical study of retinoblastoma gene product in normal, premalignant and malignant tissues of the uterine cervix. Malays J Med Sci. 2003;10(1):52-59.
  9. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143(Suppl 2):22-36.
  10. Kashyap N, Krishnan N, Kaur S, Ghai S. Risk Factors of Cervical Cancer: A Case-Control Study. Asia Pac J Oncol Nurs. 2019;6(3):308-314.
  11. Khunamornpong S, Siriaunkgul S, Manusirivithaya S, Settakorn J, Srisomboon J, Ponjaroen J, et al. Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery. Asian Pac J Cancer Prev. 2008;9(1):48-52.
  12. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical Intraepithelial Neoplasia Outcomes After Treatment: Long-term Follow-up From the British Columbia Cohort Study. JNCI Journal of the National Cancer Institute. 2009;101(10):721-728.
  13. Sugawara Y, Tsuji I, Mizoue T, Inoue M, Sawada N, Matsuo K, et al. Cigarette smoking and cervical cancer risk: an evaluation based on a systematic review and meta-analysis among Japanese women. Jpn J Clin Oncol. 2019;49(1):77-86.
  14. Gondhowiardjo SA, Kusumadjati A, Wibisono P, Sekarutami SM. Cervical Cancer Profile in dr. Cipto Mangunkusumo Hospital Year 2013. Radioter Onkol Indones. 2020;10(1):1-7.
  15. González-Yebra B, Mojica-Larrea M, Alonso R, González AL, Romero-Morelos P, Taniguchi-Ponciano K, et al. HPV infection profile in cervical lesions. Gac Med Mex. 2022;158(4):222-228.
  16. Karani LW, Musyoki S, Orina R, Kebira A, Khayeka-Wandabwa C, Nyagaka B. Human papillomavirus genotype profiles and cytological grades interlinkages in coinfection with HIV. The Pan African Medical Journal. 2020;35:67.
  17. Smith AJ, Smith LA. Viral Carcinogenesis. Prog Mol Biol Transl Sci. 2016;144:121-168.
  18. Ngan HY, Tsao SW, Liu SS, Stanley M. Abnormal expression and mutation of p53 in cervical cancer--a study at protein, RNA and DNA levels. Genitourin Med. 1997;73(1):54-58.
  19. Damayanti I. Faktor-faktor yang Berhubungan dengan Kejadian Kanker Serviks di RSUD Arifin Achmad Pekanbaru Tahun 2008-2010. Jurnal Kesehatan Komunitas. 2013;2(2):88-93.
  20. Travé G, Zanier K. HPV-mediated inactivation of tumor suppressor p53. Cell Cycle. 2016;15(17):2231-2232.
  21. Khan MA, Tiwari D, Dongre A, Sadaf, Mustafa S, Das CR, et al. Exploring the p53 connection of cervical cancer pathogenesis involving north-east Indian patients. PLOS ONE. 2020;15(9):e0238500.
  22. Schiliro C, Firestein BL. Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells. 2021;10(5):1056.
  23. Moore DH. Cervical cancer. Obstet Gynecol. 2006;107(5):1152-1161.
  24. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868.
  25. Udiyanto H, Mudigdo A, Sulistyowati S, Purwanto B, Widyaningsih V, Wasita B. A Cohort Study: Caspase-3 As Prognostic Factor of Radiation Therapy in The Advanced Stage of Cervical Cancer (IIB-IIIB) Patients. Bali Medical Journal. 2020;9(2):501-503.
  26. Mahendra INB. The characteristics of cervical cancer patients who underwent a radical hysterectomy at Sanglah Hospital Denpasar in 2015. Bali Medical Journal. 2016;5(1):237-239.
  27. Parwanto MLE, Wratsangka R, Guyansyah A, Anggraeni K. Mutation of the Fas-promoter-670 gene, AA to GA in the normal cervix-epithelial-cells of high risk Indonesian mother: A case report. Bali Medical Journal. 2019;8(1):360-364.

How to Cite

Samuel, Arifuddin, S., Lotisna, D., Cangara, M. H., & Hamid, F. (2023). Association between Human Papilloma Virus (HPV) genotype and mutant protein 53 (p53) expression in cervical cancer. Bali Medical Journal, 12(3), 2674–2680.